Markets have hinted at a sector rotation out of high-momentum stocks. High-flyers such as Tesla, Nvidia, and Square have been among the top investments over the past year. Eric Marshall, President and Director of Research for Hodges Capital Management stopped by Cheddar to discuss whether tech stocks can continue their run higher into 2018.
Marshall says he is encouraged by indications that there may be a shift to more value-oriented segments of the market. His firm is particularly optimistic for consumer-related names and transports. Marshall sees a rotation out of momentum stocks as healthy for markets, which he says keeps equity valuations in check.
Marshall also spots a turnaround for American Eagle. He says his firm likes retail at these levels because they are under-owned. Marshall adds that some retail stocks have been "thrown out with the bathwater," and thinks the adoption of e-commerce and the shutting down of stores could revive the company.
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
